Alpine Immune Sciences (ALPN) Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 Mar 21, 2024 07:45AM
Alpine Immune Sciences (ALPN) Presents New Preclinical Data on Povetacicept in Myasthenia Gravis Nov 3, 2023 09:01AM
Alpine Immune Sciences (ALPN) Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session Nov 2, 2023 09:02AM
Alpine Immune Sciences (ALPN) Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data Nov 3, 2022 04:50PM
Alpine Immune Sciences (ALPN) Appoints Andrew S. Sandler as Chief Medical Officer Jun 7, 2022 08:06AM


Jun 1, 2022 08:05AM Alpine Immune Sciences (ALPN) Provides Update on ALPN-303
Apr 4, 2022 08:06AM Alpine Immune Sciences (ALPN) Reports Key Preclinical Rationale for Davoceticept (ALPN-202)
Dec 16, 2021 08:02AM Alpine Immune Sciences (ALPN) and Horizon Therapeutics (HZNP) Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Jun 30, 2021 08:04AM Alpine Immune Sciences (ALPN) to Collaborate with Merck (MRK) on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA
Jun 2, 2021 08:04AM Alpine Immune Sciences (ALPN) Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
Apr 12, 2021 08:11AM Alpine Immune Sciences (ALPN) Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I
Jun 8, 2020 08:01AM Alpine Immune Sciences (ALPN) Presents Clinical Update of Phase 1 Trial of ALPN-101 in Healthy Volunteers
Jan 24, 2020 07:35AM Alpine Immune Sciences (ALPN) Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress
Nov 12, 2019 07:39AM Alpine Immune Sciences (ALPN) Highlights New ALPN-101 Preclinical Data at ACR 2019 Meetings
Dec 6, 2017 07:01AM Alpine Management Systems, Inc. (ALPN) Reports Preclinical Data on Novel Immuno-Oncology Molecules from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Nov 10, 2017 07:01AM Alpine Management Systems, Inc. (ALPN) Reports Preclinical Data on Novel Immuno-Oncology Molecules